Ser563
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser563  -  NHE3 (human)

Site Information
LAFIRSPstDNVVNV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12265540

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , melanoma skin cancer ( 3 , 4 )
Relevant cell line - cell type - tissue:
lung ( 2 ) , skin ( 3 , 4 )

References 

1

Han Y, Bagchi P, Yun CC (2024) Regulation of the intestinal Na/H exchanger NHE3 by AMP-activated kinase is dependent on phosphorylation of NHE3 at S555 and S563. Am J Physiol Cell Physiol 326, C50-C59
38047302   Curated Info

2

Rikova K (2010) CST Curation Set: 9010; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

3

Tucker M (2009) CST Curation Set: 8377; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

4

Tucker M (2009) CST Curation Set: 8385; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info